Cristina Ramo‐Tello

Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study

Ludwig Kappos, Amit Bar‐Or, Bruce Cree et al. · The Lancet · 2018 · 925 citations

Medicine, Neurology, Pharmacology +9

Defining secondary progressive multiple sclerosis

Johannes Lorscheider, Katherine Buzzard, Vilija Jokubaitis et al. · Brain · 2016 · 416 citations · Full text

Life Sciences, Neurology, Neuroscience +12

Defining reliable disability outcomes in multiple sclerosis

Tomáš Kalinčík, Gary Cutter, Tim Spelman et al. · Brain · 2015 · 243 citations · Full text

Medicine, Neurology, Disability Management +16

Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study

Tomáš Kalinčík, J William L Brown, Neil P. Robertson et al. · The Lancet Neurology · 2017 · 162 citations · Full text

Life Sciences, Neurology, Pharmacotherapy +16

Neuromyelitis optica spectrum disorders

María Sepúlveda, Thaís Armangué, Núria Solà‐Valls et al. · Neurology Neuroimmunology & Neuroinflammation · 2016 · 152 citations · Full text

Medicine, Neurology, Immunopathology +14